Table 1: Solvay - PharmaVitae forecasts at a glance 7
Table 2: Solvay gross profit margin analysis, 2001-07 9
Table 3: Solvay's lipid management portfolio 11
Table 4: Solvay operating cost ratio analysis (% of total revenues), 2007-13 17
Table 5: Solvay key product developments, Q1-Q3 2008 28
Table 6: Solvay product deals and alliances, Q1-Q3 2008 29
Table 7: Solvay technology deals and alliances, Q1-Q3 2008 29
Table 8: Solvay M&A activity, Q1-Q3 2008 30
Table 9: Solvay company announcements, Q1-Q3 2008 30
Table 10: Solvay future product milestones, 2008-10 31
Table 11: Solvay product portfolio overview ($m), 2001-07 42
Table 12: Solvay product portfolio overview ($m), 2007-13 46
Table 13: Solvay product portfolio overview ($m), 2001-07 52
Table 14: Solvay product portfolio overview ($m), 2007-13 54
Table 15: Solvay portfolio overview by geographic region ($m), 2001-07 58
Table 16: Solvay portfolio overview by geographic region ($m), 2007-13 60
Table 17: Solvay launch portfolio overview ($m), 2007-13 64
Table 18: Solvay core portfolio overview ($m), 2007-13 65
Table 19: Solvay expiry portfolio overview ($m), 2007-13 66
Table 20: Solvay portfolio overview by molecule type ($m), 2001-07 69
Table 21: Solvay product portfolio overview by molecule type ($m), 2007-13 70
Table 22: Solvay product portfolio overview by source ($m), 2001-07 73
Table 23: Solvay product portfolio overview by source ($m), 2007-13 75
Table 24: Total Solvay sales by business unit ($m), 2001-07 79
Table 25: Solvay profit and loss account ($m), 2001-07 81
Table 26: Solvay balance sheet ($m), 2001-07 83
Table 27: Solvay operating revenue/cost analysis ($m), 2001-07 86
Table 28: Solvay operating cost ratio analysis (% of total revenues), 2001-07 87
Table 29: Solvay operating cost ratio analysis (% of total revenues), 2007-13 88
Table 30: Solvay operating revenue/cost analysis ($m), 2007-13 90
Table 31: Solvay capital employed ($m), 2001-07 93
Table 32: Solvay EBIT return on capital employed ($m), 2001-07 95
Table 33: Solvay EBIT pre-tax return/capital employed driver analysis (%), 2001-07 96
Table 34: Solvay market capitalization ($ billion), 2000-07 98
Table 35: Solvay total shareholder returns (annual %), 2001-07 100
Table 36: Key products overview 102
Table 37: TriCor: overview 104
Table 38: TriLipix: overview 105
Table 39: TriCor: sales forecast ($m), 2007-13 106
Table 40: TriLipix: sales forecast ($m), 2007-13 106
Table 41: Major dyslipidemia therapeutics, global sales ($m), 2001-07 109
Table 42: AndroGel: overview 113
Table 43: AndroGel: sales forecast ($m), 2007-13 114
Table 44: Creon: overview 119
Table 45: Creon: sales forecast ($m), 2007-13 120
Table 46: Serc: overview 123
Table 47: Serc: sales forecast ($m), 2007-13 124
Table 48: Influvac: overview 127
Table 49: Influvac: sales forecast ($m), 2007-13 128
Table 50: Solvay's R&D pipeline (Phase I-registration) 131
Table 51: Exchange rates, 2007 134
Figure 1: Solvay prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Solvay's financial performance ($m), 2001-13 6
Figure 3: Financial performance lifted by restructuring efforts 8
Figure 4: Focus on pharma performance ($m), 2001-07 10
Figure 5: Solvay's lipid management portfolio, sales ($m), 2001-13 14
Figure 6: Solvay SWOT analysis 18
Figure 7: Current corporate structure 36
Figure 8: Solvay prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 39
Figure 9: Solvay key sales growth drivers and resistors ($m), 2001-07 43
Figure 10: Solvay key sales growth drivers and resistors ($m), 2007-13 47
Figure 11: Solvay prescription pharmaceutical sales by therapy area ($m), 2001-13 51
Figure 12: Solvay prescription pharma sales by therapy area (% of total), 2001-13 56
Figure 13: Solvay prescription pharmaceutical sales by geographic region ($m), 2001-13 57
Figure 14: Solvay growth drivers and resistors by geographic region ($m), 2001-07 58
Figure 15: Solvay drivers and resistors by geographic region ($m), 2007-13 60
Figure 16: Solvay prescription pharmaceutical sales by geographic region (% of total), 2001-13 62
Figure 17: Solvay launch/core/expiry configuration ($m), 2007-13 67
Figure 18: Solvay prescription pharmaceutical sales by molecule type ($m), 2001-13 68
Figure 19: Solvay growth drivers and resistors by molecule type ($m), 2007-13 71
Figure 20: Solvay prescription pharmaceutical sales by source ($m), 2001-13 72
Figure 21: Solvay growth drivers and resistors by source ($m), 2001-07 73
Figure 22: Solvay growth drivers and resistors by source ($m), 2007-13 76
Figure 23: Solvay operating revenue/cost analysis ($m), 2001-13 85
Figure 24: Solvay operating cost ratio analysis (% of total revenues), 2001-13 89
Figure 25: Solvay return on capital employed, EBIT margin and capital turnover, 2001-07 92
Figure 26: Return on capital employed formula 96
Figure 27: Solvay market capitalization ($ billion), 2001-07 99
Figure 28: Solvay total shareholder returns vs. S&P 500 ($m), 2001-07 100
Figure 29: Global testosterone market (% total sales), Q103-Q407 116
[Tabellenverzeichnis ausblenden]
